Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)

NCT02198651 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02198651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02198651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Completed
Start date
January 5, 2015
Completion date
August 8, 2018
Enrollment
149 (actual)
Sites
70

Conditions

As the registry lists them; a condition with its own page is linked.

musculoskeletal and connective tissue diseases, rheumatoid arthritis